What is Zacks Research’s Forecast for ESPR FY2027 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at Zacks Research lowered their FY2027 earnings per share estimates for shares of Esperion Therapeutics in a research note issued to investors on Monday, July 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of $0.05 for the year, down from their prior forecast of $0.06. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

A number of other equities analysts have also commented on ESPR. The Goldman Sachs Group lowered their price objective on Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. Needham & Company LLC lowered their price objective on Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $1.41 on Tuesday. The stock’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $1.35. Esperion Therapeutics has a one year low of $0.69 and a one year high of $3.94. The firm has a market cap of $279.46 million, a PE ratio of -1.76 and a beta of 0.70.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 59.03%. The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million.

Institutional Investors Weigh In On Esperion Therapeutics

Large investors have recently modified their holdings of the business. Sivia Capital Partners LLC acquired a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at $25,000. North Star Investment Management Corp. acquired a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at $25,000. Meridian Wealth Management LLC acquired a new stake in shares of Esperion Therapeutics during the 1st quarter valued at $29,000. Synergy Asset Management LLC boosted its holdings in shares of Esperion Therapeutics by 3,496.3% during the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 30,138 shares in the last quarter. Finally, Boomfish Wealth Group LLC boosted its holdings in shares of Esperion Therapeutics by 29.5% during the 2nd quarter. Boomfish Wealth Group LLC now owns 45,306 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 10,309 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.